Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,879 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Expectant Management Clear all
Completed No phase listed Observational

A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment

NCT06147830
View directory record Official record
Conditions
Major Bleeding
Interventions
None (Observational study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
2,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
25
States / cities
Chandler, Arizona • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 20, 2026, 11:10 PM EDT
Recruiting Phase 3 Interventional

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328
View directory record Official record
Conditions
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
332
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 20, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

NCT06043674
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Richter's Transformation
Interventions
Glofitamab, Obinutuzumab, Polatuzumab Vedotin, Atezolizumab, Tocilizumab, Pirtobrutinib
Drug
Lead sponsor
Christine Ryan
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 20, 2026, 11:10 PM EDT
Completed No phase listed Observational

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

NCT01476956
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Observational study
Other
Lead sponsor
CARE ARTHRITIS LTD.
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 20, 2026, 11:10 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

NCT04271475
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
24
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 3 Interventional

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

NCT00242840
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
No intervention; Observational study
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
6
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Not applicable Interventional

Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes

NCT03307850
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Observation During Exercise and Stress
Other
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Santa Barbara, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Not applicable Interventional

Testing LEIFc in the Community

NCT06898190
View directory record Official record
Conditions
Responsive Infant Feeding, Infant Growth
Interventions
Learning Early Infant Feeding Cues (LEIFc)
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies

NCT01036009
View directory record Official record
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia, Pre-leukemic Syndromes, Monosomy 7, Bone Marrow Clonal Malformations, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
Interventions
Withdrawal of immunosuppression and donor lymphocyte infusion
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Months to 25 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
San Francisco, California • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 20, 2026, 11:10 PM EDT
Terminated No phase listed Observational

Correlation Of Respiratory Rate Level And Trend Evaluation in Heart Failure Patients

NCT00758121
View directory record Official record
Conditions
Heart Failure
Interventions
Cardiac Resynchronization Therapy Defibrillator
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2009 · Synced Oct 20, 2026, 11:10 PM EDT
Not yet recruiting Not applicable Interventional

Signatera Assessment in Early-Stage Endometrial Cancer

NCT07339384
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Signatera Genome ultra-sensitive ctDNA blood test
Device
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 20, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Results available

Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

NCT00656916
View directory record Official record
Conditions
Bronchiolitis
Interventions
Fluticasone Propionate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

NCT03325816
View directory record Official record
Conditions
Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Interventions
Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation for Prostate Oligometastases

NCT02680587
View directory record Official record
Conditions
Prostate Cancer, Oligometastases
Interventions
SBRT
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

NCT00716976
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ototoxicity, Ovarian Cancer, Sarcoma
Interventions
sodium thiosulfate, examination
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 18 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
68
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 20, 2026, 11:10 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Vaccine Observation to Include All Communities for Equitable Science

NCT04770649
View directory record Official record
Conditions
Vaccine Response Impaired, Vaccine Adverse Reaction
Interventions
COVID-19 vaccine
Biological
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 20, 2026, 11:10 PM EDT
Terminated Not applicable Interventional Results available

Developing a Pain Identification and Communication Toolkit

NCT03853291
View directory record Official record
Conditions
Dementia, Chronic Pain
Interventions
PICT Workbook, Information Pamphlet
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 100 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 20, 2026, 11:10 PM EDT
Recruiting No phase listed Observational

European Prospective Investigation Into Childhood Cancer

NCT05375617
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Brain Tumor
Interventions
Observational
Other
Lead sponsor
Columbia University
Other
Eligibility
3 Years to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 20, 2026, 11:10 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT02445391
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1023
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 11:10 PM EDT
Active, not recruiting Phase 2 Interventional

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

NCT03059485
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
DC/AML Fusion Vaccine, Observation
Biological · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 11:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

COVID-19: Human Epidemiology and Response to SARS-CoV-2

NCT04375761
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
Interventions
Collection of Biological Samples, Symptom and Exposure Surveys
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
5,599 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
20
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
View directory record Official record
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 20, 2026, 11:10 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Frequency and Persistence of Wide Pulse Pressure in the Neonatal Population

NCT01682122
View directory record Official record
Conditions
Blood Pressure, Pediatrics, Infant, Newborn, Cardiology
Interventions
Not listed
Lead sponsor
Staten Island University Hospital
Other
Eligibility
Up to 72 Hours
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 20, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

NCT03126331
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 20, 2026, 11:10 PM EDT